Naumova Natalia, Alikina Tatiana, Tupikin Alexey, Kalmykova Anna, Soldatova Galina, Vlassov Valentin, Kabilov Marsel
Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva 8, Novosibirsk, Russia 630090.
Bio-Vesta LLC, Novosibirsk, Russia.
Indian J Microbiol. 2020 Dec;60(4):451-457. doi: 10.1007/s12088-020-00888-1. Epub 2020 May 25.
Gut microbiota is believed to play a crucial role in modulating obesity in humans, and probiotics affecting gut microbiota can alleviate some of the obesity-related health complications. The study was aimed to investigate changes in the composition of the gut microbiome in obese humans due to short-term (2 weeks) treatment of obese patients with a probiotic preparation containing . Faecal microbiome diversity was studied using the 16S amplicon sequencing by Illumina MiSeq. Bioinformatic analysis showed distribution across 14 phyla (with and dominating), 21 class, 125 genera and 973 OTUs. The probiotic treatment decreased relative abundance of ( and ), while increasing that of ( and ), and (: and : ). The probiotic treatment decreased total blood sugar and increased patients' assessment of their physical and mental health. Thus even the short-term -based probiotic treatment brought significant compositional changes in the 16S rRNA gene diversity in faecal bacterial assemblages by increasing beneficial and decreasing pathogenic or opportunistic bacteria; the related shifts in life quality assessment necessitate further research into the causal relationships involved.
肠道微生物群被认为在调节人类肥胖方面起着关键作用,影响肠道微生物群的益生菌可以缓解一些与肥胖相关的健康并发症。该研究旨在调查肥胖患者短期(2周)使用含益生菌制剂治疗后肠道微生物组组成的变化。通过Illumina MiSeq的16S扩增子测序研究粪便微生物组多样性。生物信息学分析显示分布在14个门(以[具体门名1]和[具体门名2]为主)、21个纲、125个属和973个操作分类单元。益生菌治疗降低了[具体菌属1]([具体菌属1的两个亚类]和[具体菌属1的另两个亚类])的相对丰度,同时增加了[具体菌属2]([具体菌属2的两个亚类]和[具体菌属2的另两个亚类])以及[具体菌属3]([具体菌属3的两个亚类]:[具体菌属3的一个亚类]和[具体菌属3的另一个亚类]:[具体菌属3的另一个亚类])的相对丰度。益生菌治疗降低了总血糖并提高了患者对其身心健康的评估。因此,即使是基于[具体益生菌]的短期治疗也通过增加有益菌和减少致病或机会性细菌,使粪便细菌群落中16S rRNA基因多样性发生了显著的组成变化;生活质量评估中的相关变化需要进一步研究其中的因果关系。